Natalizumab-related PML in multiple sclerosis: a case report

被引：0
|
作者：
Papadopoulos, D.
Plafadeli, A.
Zafeiropoulou, E.
Kontogeorgi, E.
Alexopoulos, H.
Veretzioti, A.
Zisimopoulou, V.
Dalakas, M. C.
Tavernarakis, A.
机构：
[1] Evangelismos Gen Hosp, Athens, Greece
[2] Univ Athens, Athens, Greece
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S109 / S110
页数：2
相关论文
共 50 条
  • [31] Unusual course and manifestation of natalizumab associated PML in a patient with multiple sclerosis
    Kuempfel, T.
    Havla, J.
    Lippmann, K.
    Hohlfeld, R.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 142 - 142
  • [32] Search of biomarkers for PML risk in multiple sclerosis patients receiving natalizumab
    Comabella, M.
    Fissolo, N.
    Matute, C.
    Trivino, J. C.
    Pignolet, B.
    Rodriguez, O.
    Vidal-Jordana, A.
    Rio, J.
    Montalban, X.
    Brassat, D.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 456 - 456
  • [33] Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature
    Magistrelli, Luca
    Vecchio, Domizia
    Naldi, Paola
    Comi, Cristoforo
    Cantello, Roberto
    NEUROLOGICAL SCIENCES, 2019, 40 (09) : 1943 - 1945
  • [34] Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
    Honce, Justin M.
    Nagae, Lidia
    Nyberg, Eric
    MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
  • [35] Natalizumab-related progressive multifocal leukoencephalopathy in Greece
    Mitsikostas, Dimos D.
    Mastorodemos, Vasileios
    Tsagournizakis, Minas
    Kodounis, Antonios
    Tsagkaropoulos, Antonios
    Konitsiotis, Spyridon
    Toulas, Panagiotis
    Papadimitriou, Alexandros
    Papadimitriou, Dimitra
    Tavernarakis, Antonios
    Papadopoulos, Dimitrios
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (02) : 203 - 210
  • [36] Fingolimod/natalizumabReactivation of multiple sclerosis following natalizumab withdrawal: case report
    Reactions Weekly, 2013, 1433 (1) : 22 - 22
  • [37] PML in natalizumab-treated multiple sclerosis Modeling errors and risk miscalculations
    Mowry, Ellen M.
    McArthur, Justin C.
    NEUROLOGY, 2017, 88 (12) : 1110 - 1111
  • [38] Review on PML Risk Stratification in Natalizumab-Treated Multiple Sclerosis Patients
    Grigoriadis, Nikolaos C.
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 61 - 63
  • [39] Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab
    Putzki, N.
    Clifford, D. B.
    Bischof, D.
    Moore, A.
    Weinshenker, B. G.
    Freedman, M. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 43 - 43
  • [40] Expanded Laboratory Surveillance for PML in a Large Cohort of Patients on Natalizumab for Multiple Sclerosis
    Amezcua, Lilyana
    Berkovich, Regina
    Burnett, Margaret
    Aparicio, Jose
    Kachuck, Norman
    NEUROLOGY, 2010, 74 (09) : A419 - A419
12345